NCT02187302 2020-05-28CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)Lumos PharmaPhase 2 Completed115 enrolled
NCT01625936 2018-08-29CRLX101 Plus Bevacizumab in Advanced RCCAbramson Cancer Center at Penn MedicinePhase 1 Completed22 enrolled